Labiotech.eu

News and Trends 26 Jul 2022

Pleco Therapeutics expands into U.S. and names president

Pleco Therapeutics BV, a biopharmaceutical company based in the Netherlands, has expanded, with the incorporation of a U.S. subsidiary, Pleco Therapeutics USA. Pleco Therapeutics, which develops novel treatments designed to detoxify the cancer promoting cellular micro-environment, also named Michael Stalhamer as the US subsidiary’s president and first employee. Stalhamer also serves on the global leadership […]

July 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 26 Jul 2022

InflaRx announces plans to apply for Emergency Use Authorization for new COVID-19 drug

A biopharmaceutical company developing anti-inflammatory therapeutics announced today (July 26) that it is going to submit a request for Emergency Use Authorization (EUA). InflaRx made the announcement after encouraging interactions with the US Food and Drug Administration (FDA) at a recent meeting. The company had requested the meeting to discuss a potential EUA submission regarding […]

July 26, 2022 - 2 minutesmins - By Liza Laws

News and Trends 26 Jul 2022

Irish agritech start-up CropBiome receives €1.3M investment

Irish agritech startup CropBiome, a joint University College Dublin (UCD) and Trinity College Dublin (TCD) spin-out, has received €1.3 million ($1.3 million) funding. HBAN (Halo Business Angel Network), the all-island organization responsible for the promotion of business angel investment, and a joint initiative of Enterprise Ireland, InterTradeIreland and Invest Northern Ireland, participated in the oversubscribed […]

July 26, 2022 - 5 minutesmins - By Jim Cornall

cancer shutterstock immunotherapy deep science ventures

News and Trends 26 Jul 2022

Deep Science Ventures deepens CRUK pact to co-found oncology startups

The venture builder Deep Science Ventures (DSV) has expanded an existing alliance with Cancer Research UK’s innovation-focused arm Cancer Research Horizons, with the mission to establish new oncology startups in the U.K. Just months after Cancer Research UK (CRUK) established its industry-orientated division Cancer Research Horizons, the research charity has doubled down on a collaboration […]

July 26, 2022 - 3 minutesmins - By Jonathan Smith

News and Trends 26 Jul 2022

Oxford Biomedica sets up new project and signs LSA

Oxford Biomedica plc, a UK-based gene and cell therapy group, has initiated a new project with Orchard Therapeutics utilizing the company’s LentiStable technology. The group also announced the signing of a new licence and supply agreement (LSA) with an undisclosed US-based private biotech company advancing a new generation of adoptive cell therapies. LentiStable technology As […]

July 26, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 26 Jul 2022

Catalonia health startup investments in 2022 top €296M to overtake 2021 tally

Life sciences organization Biocat says midyear investment in startups in the BioRegion of Catalonia in Spain is 2.5 times higher than the same period last year, at €296 million ($301 million). The total for the entire year 2021 was €238 million ($242 million). The first semester included a round of €100 million ($101.8 million) by […]

July 26, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 26 Jul 2022

Israeli foodtech company develops zero-waste plant protein extraction

A novel, waste-free protein extraction method that completes the sustainability loop through the sustainability practice of upcycling has been created by Acre, Israel-Gavan Technologies, Ltd. The foodtech start-up supports the circular economy by positioning total plant extraction at the core of its operations. Itai Cohen, CEO and co-founder of Gavan, said: “Our new, multistep technological […]

July 26, 2022 - 4 minutesmins - By Liza Laws

News and Trends 26 Jul 2022

New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA

A drug candidate for unresectable or metastatic breast cancer has been accepted by the US Food and Drug Administration (FDA). The drug is being jointly developed and commercialized and the result of a high-profile partnership between AstraZeneca and Daiichi Sankyo. Enhertu (trastuzumab deruxtecan) is a specifically engineered HER2-directed antibody drug conjugate (ADC). Acceptance The companies received […]

July 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Jul 2022

Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens

Finnish immunotherapy company Valo Therapeutics Oy (ValoTx) has obtained exclusive licensing of intellectual property rights (IPR) from the University of Helsinki, Finland, for the institution’s PeptiCHIP technology. Following further validation by ValoTx, and the achievement of specific milestones, the IPR will transfer in full to the company. Valo said the deal will enable the rapid […]

July 26, 2022 - 2 minutesmins - By Jim Cornall

In Depth 26 Jul 2022

How DNA sequencing can safeguard against biodiversity loss

Preserving Earth’s biodiversity is crucial as we rely on healthy ecosystems for many services, from clean air and water to protection from floods and pandemics. DNA sequencing is an invaluable tool for characterizing biodiversity and informing conservation efforts. In Earth’s history, there have been five major mass extinction events — the most recent of which […]

July 26, 2022 - 8 minutesmins - By Omnia Ibrahim

News and Trends 26 Jul 2022

Ginkgo acquires Zymergen for $300M and picks up Bayer facility for $83M

U.S. cell programming company Ginkgo Bioworks has signed definitive agreements to acquire two teams and technologies. The deals are with Bayer and Zymergen. Bayer transaction The company confirmed the previously announced transaction with Bayer to expand Ginkgo’s platform capabilities in agricultural biologicals. Ginkgo will acquire Bayer’s 175,000-square-foot West Sacramento Biologics Research & Development site, team, […]

July 26, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 25 Jul 2022

Drug that could be the first and only in Europe to treat rare brain condition recommended for marketing authorization

The Committee for Medical Products for Human Use (CHMP) has recommended the European Commission (EC) make a marketing authorization under exceptional circumstances for a drug to treat a rare condition characterized by brain dysfunction. The drug is called NULIBRY (fosdenopterin) for injection therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. […]

July 25, 2022 - 4 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Pleco Therapeutics expands into U.S. and names president

InflaRx announces plans to apply for Emergency Use Authorization for new COVID-19 drug

Irish agritech start-up CropBiome receives €1.3M investment

Deep Science Ventures deepens CRUK pact to co-found oncology startups

Oxford Biomedica sets up new project and signs LSA

Catalonia health startup investments in 2022 top €296M to overtake 2021 tally

Israeli foodtech company develops zero-waste plant protein extraction

New AstraZeneca and Daiichi Sankyo breast cancer drug accepted by FDA

Valo Therapeutics acquires PeptiCHIP technology to identify tumor antigens

How DNA sequencing can safeguard against biodiversity loss

Ginkgo acquires Zymergen for $300M and picks up Bayer facility for $83M

Drug that could be the first and only in Europe to treat rare brain condition recommended for marketing authorization

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!